3 Reliable Dividend Stocks for Uncertain Times: Coca-Cola, AbbVie, and McDonald’s

NYSE: KO | Coca-Cola Company News, Ratings, and Charts

KO – Coca-Cola (KO), AbbVie (ABBV) and McDonald’s (MCD) have paid attractive dividends consistently over the years. Even amid the rising unemployment wrought by the COVID-19 pandemic, we think these companies should continue to be a safe bet dividend-payment wise considering their financial strength and industry dominance. Let us discuss.

Prior to the pandemic, only retired people and Trusts and Foundations generally preferred investing in dividend-yielding stocks. But this stereotype no longer holds. With millions of people unemployed now due to a pandemic-driven global recession, dividend stocks have gained popularity as investors seek alternative sources of income.

This environment, accompanied by Fed’s near-zero interest rate policy, has propelled many investors, seeking stability and income, to divert capital towards dividend stocks. The Vanguard High Dividend Yield ETF (VYM) has gained 13.4% over the past six months reflecting investors’ move toward high dividend-yielding stocks.

The Coca-Cola Company (KO), AbbVie Inc. (ABBV) and McDonald’s Corporation (MCD) have been able to deliver regular dividends over the years and should be good bets now.

The Coca-Cola Company (KO)

The world’s largest beverage company needs no introduction. Operating worldwide, the company markets more than 500 non-alcoholic beverage brands including Coca-Cola, Diet Coke, Fanta, Thumbs Up, and Sprite.

KO pays $1.64 in dividends annually, yielding 3.1% at its current price. It has a payout ratio of 86.5% of the net income. The company’s dividend payments have grown at a CAGR of 5.6% over the past five years.

KO’s Non-GAAP operating margin has increased 230 basis points year-over-year to 30.4% in the third quarter ended September 30, 2020.

Analysts expect KO’s EPS to rise 11.6% to $2.12 for the next year ending December 31, 2021. The company has an impressive earnings surprise history; it beat the Street EPS estimates in three of the trailing four quarters. The consensus revenue estimate of $36.55 billion for the next year indicates a 10.5% rise. KO has gained 14.4% over the past six months.

How does KO stack up for the POWR Ratings?

A for Trade Grade

B Buy & Hold Grade

B for Peer Grade

A for Industry Rank

B for Overall POWR Rating.

It is currently ranked #10 of 29 stocks in the Beverages industry.

AbbVie Inc. (ABBV)

ABBV is a research-based biopharmaceutical company. It manufactures and sells a range of pharmaceutical products around the world. Its product line includes: Oncology products, Virology Products, Additional Virology products, Metabolic/Hormones products, Endocrinology products, HUMIRA, and others.

ABBV entered a strategic partnership with Frontier Medicines, Corp. this month to discover, develop and market a pipeline of innovative small molecule therapeutics. The partnership will enable ABBVto utilize Frontier’s proprietary chemo proteomics platform to develop the required drugs.

ABBV pays $5.20 in dividends annually, yielding 4.96% at its current price. It has a payout ratio of 49.6% of the net income. The company’s dividend payments have grown at a CAGR of 20.9% over the past five years.

ABBV’s revenues have increased 52.1% year-over-year to $12.9 billion in the third quarter ended September 30, 2020. Operating profit increased 24.4% from the year-ago value to $3.26 billion, while its Non-GAAP EPS rose 21.5% from the same period last year to $2.83. Its free cash flow has increased 27.5% year-over-year to $5.61 billion.

The consensus EPS estimate of $2.86 for the current quarter ending December 31, 2020 indicates a 29.4% rise year-over-year. The company has an impressive earnings surprise history as well; it beat the Street EPS estimates in each of the trailing four quarters. The consensus revenue estimate of $13.73 billion for the current quarter represents a 57.7% improvement from the year-ago value. ABBV has gained 16.4% over the past year.

ABBV’s POWR Ratings reflect this promising outlook. It has an overall rating of “Strong Buy” with an “A” for Trade Grade, Peer Grade, Buy & Hold Grade and Industry Rank. Among the 240 stocks in the Medical – Pharmaceuticals industry, it’s ranked #3.

McDonald’s Corporation (MCD)

MCD operates and franchises approximately 38,695McDonald’s restaurants around the globe. Its target market includes primarily the United States as well as, high growth markets, foundational markets, and corporations.

In early November, MCD announced a new growth strategy: Accelerating the Arches. With the strategy, the company is focused on updating its actions and behaviors, and growth pillars by leveraging its competitive advantage. This will help MCD increase its market reach and customer base further.

MCD pays $5.16 in dividends annually, yielding 2.41% on its current price. It has a payout ratio of 83.16% of net income. The company’s dividend payments have grown at a CAGR of 7.6% over the past five years.

MCD Net Income has increased 9.3% year-over-year to $1.76 billion in the third quarter ended September 30, 2020. Operating profit increased 5% from the year-ago value to $2.53 billion, while its Non-GAAP EPS rose 5.2% from the same period last year to $2.22. Its free cash flow increased 900.2% year-over-year to $428.1 million.

Analysts expect MCD’s EPS to rise 34.1% to $8.34 for the next year ending December 31, 2021. The consensus revenue estimate of $5.39 billion for the current quarter ending December 31, 2020 represents a slight rise year-over-year. The stock has gained 9% over the past year.

MCD is rated a “Buy” in our POWR Ratings system. It has a “B” for Trade Grade, Buy & Hold Grade, and Industry Rank. In 49-stock Restaurant Industry, it is ranked #2.

Want More Great Investing Ideas?

“MUST OWN” Growth Stocks for 2021

Where is the Santa Claus Stock Rally?

5 WINNING Stocks Chart Patterns


KO shares were unchanged in after-hours trading Friday. Year-to-date, KO has gained 0.41%, versus a 16.35% rise in the benchmark S&P 500 index during the same period.


About the Author: Rishab Dugar


Rishab is a financial journalist and investment analyst. His investment approach is to focus on quality stocks, trading at low prices, with business models that he readily understands. More...


More Resources for the Stocks in this Article

TickerPOWR RatingIndustry RankRank in Industry
KOGet RatingGet RatingGet Rating
ABBVGet RatingGet RatingGet Rating
MCDGet RatingGet RatingGet Rating

Most Popular Stories on StockNews.com


Updated 2024 Stock Market Outlook

The bull market continues to rage on with the S&P 500 (SPY) making new highs. That is the past...the question is what does the future hold? That is why 44 year investment veteran Steve Reitmeister provides this updated 2024 Stock Market Outlook to help you carve a path to outperformance the rest of the year. Read on below for the full story...

Top 4 Tech Giants Poised for Explosive Growth

Fueled by the ever-growing demand for advanced technological solutions across various sectors and ongoing innovation, the tech industry has robust growth prospects. Thus, it could be wise to invest in top tech stocks Dropbox (DBX), TTM Technologies (TTMI), Lantronix (LTRX) and AstroNova (ALOT) for potential growth. Continue reading…

3 Top Rated Software Stocks to Streamline Your Investments

The software industry is thriving with soaring demand, presenting ample investment opportunities. So, fundamentally solid software stocks ServiceNow (NOW), Autodesk (ADSK), and Docebo (DCBO) might be ideal buys for promising returns. Read on...

Biotech Investors: Should You Buy, Hold, or Sell Moderna (MRNA) and Arrowhead Pharmaceuticals (ARWR)?

Despite facing several challenges, the biotech sector thrives due to growing demand for effective treatments, consistent innovations, and a sustained demand for high-quality drugs and therapies. Let's assess whether one should Buy, Hold, or Sell biotech stocks Moderna (MRNA) and Arrowhead Pharmaceuticals (ARWR). Keep reading...

Investor Alert: “Buy the Rumor, Sell the News!”

Everyone knows that the Fed is going to cut rates at some point this year. That is the worst kept secret on the planet helping to explain how we keep making new highs for the for the S&P 500 (SPY). Unfortunately that creates an interesting predicament for stocks after rates are cut. Plus another hurdle in the 2024 Presidential election. Steve Reitmeister is here to share his insights on the market outlook along with a preview of his top 12 stocks to outperform. Read on for more...

Read More Stories

More Coca-Cola Company (KO) News View All

Event/Date Symbol News Detail Start Price End Price Change POWR Rating
Loading, please wait...
View All KO News